Deschloroetizolam is a synthetic thienodiazepine and a structural analog of etizolam, differing only in the absence of the chlorine substituent on the thiophene ring. Like etizolam, it produces typical benzodiazepine-like effects — anxiolysis, sedation, muscle relaxation, and anticonvulsant activity — through positive allosteric modulation of GABA-A receptors. It appeared on the research chemical market primarily as a legal alternative to etizolam in jurisdictions where etizolam had been scheduled.
Deschloroetizolam is considerably less well-characterized than etizolam. Clinical and pharmacological data are sparse, and most knowledge of its effects comes from user reports. Community experience suggests it is somewhat less potent than etizolam on a milligram-for-milligram basis, with a similar duration of action and general effect profile. Its lower potency, while potentially suggesting a slightly wider absolute safety margin, does not eliminate the risks of respiratory depression with concurrent CNS depressants, tolerance, physical dependence, and severe withdrawal that characterize all benzodiazepine-class compounds.
As a designer thienodiazepine with limited pharmacological characterization, deschloroetizolam exemplifies the risks associated with novel psychoactive substances in the GABAergic depressant class: an absence of clinical dose-finding, no established therapeutic protocols, and an addiction and withdrawal risk equivalent to pharmaceutical benzodiazepines.
Safety at a Glance
High Risk- Weigh Doses Accurately
- Without clinical dose-finding data, an initial dose should be conservative — a fraction of what user reports suggest ...
- Toxicity: Class Risk Profile Deschloroetizolam shares the risk profile of all GABA-A positive allosteric modulators. Sole-agent...
- Dangerous with: 1,4-Butanediol, 2M2B, Acetylfentanyl, Alcohol (+59 more)
- Overdose risk: Overdose Thienodiazepine overdose may occur when a thienodiazepine is taken in extremely heavy qu...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 8 hrs – 10 hrsHow It Feels
Deschloroetizolam eases into the body with the gentle insistence of a tide coming in on a calm shore. Within thirty to forty-five minutes, the first effects manifest as a softening of the anxious edge that accompanies daily life. The shoulders relax by a fraction, the jaw unclenches, and there is a quiet warmth that spreads through the chest and abdomen. The change is subtle enough that you might not notice it happening -- only that the world seems slightly less abrasive than it did half an hour ago.
As the thienobenzodiazepine reaches its full expression, the anxiolytic effects become more pronounced. There is a pleasant detachment from worry, a sense of emotional insulation that does not numb so much as buffer. Thoughts continue to flow but they have lost their thorns; problems can be considered without the accompanying spike of cortisol. The body settles into a state of mild relaxation -- muscles looser, breathing slower, the physical markers of stress gently erased. There is a light sedation present, but it sits in the background rather than commanding attention. You can still function, still think, still engage with the world; the substance simply lowers the stakes of doing so.
At the peak, the experience plateaus into a steady state of calm functionality. This is not a substance that produces dramatic peaks or valleys; its virtue lies in its evenness. There is a mild muscle relaxation that makes the body feel comfortable and at ease, and an emotional equanimity that makes social interaction feel effortless. Some users report a gentle uplift in mood -- not euphoria exactly, but a quiet contentment, like the feeling of returning home after a long day. Coordination remains largely intact, though reaction times may be slightly slowed. Memory is generally preserved, though events may be recorded with slightly less vividness than usual, as though the contrast has been turned down a notch.
The comedown is a gradual, almost imperceptible return to baseline over several hours. The calm does not crash but fades, like the last light of evening giving way to twilight and then darkness. There is no hangover to speak of, no rebound anxiety, just a smooth transition back to the ordinary texture of consciousness. Sleep, if sought during the tail end of the experience, comes easily and tends to be restful.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(7)
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Cognitive & Perceptual Effects
Cognitive(14)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Delirium— Delirium is a serious and potentially dangerous state of acute mental confusion involving disorienta...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Emotion suppression— A blunting or flattening of emotional experience in which feelings become muted, distant, or seeming...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
Pharmacology
Mechanism of Action
Deschloroetizolam is a positive allosteric modulator of GABA-A receptors, acting at the benzodiazepine binding site between the α and γ subunits of the receptor complex. Like all benzodiazepine-class compounds, it increases the frequency of chloride channel opening in response to GABA, enhancing inhibitory neurotransmission throughout the CNS.
Thienodiazepine Structure
Thienodiazepines replace the benzene ring of classical benzodiazepines with a thiophene ring. This structural modification generally results in compounds with high potency and somewhat altered receptor kinetics, but does not fundamentally change the mechanism of action. The parent compound etizolam has been extensively studied and functions as a full benzodiazepine-site agonist.
Comparison to Etizolam
Deschloroetizolam differs from etizolam only in lacking the chlorine atom at position 4 of the thiophene ring. Structure-activity relationship data for the thienodiazepine series suggest this chlorine atom enhances potency; accordingly, deschloroetizolam is generally considered less potent than etizolam, with user reports suggesting it may require somewhat higher doses to achieve comparable effects. The clinical relevance of this potency difference, in terms of safety margin, is modest.
Pharmacokinetics
Specific pharmacokinetic data for deschloroetizolam are limited. By structural analogy with etizolam, oral bioavailability is expected to be good, with onset within 30–60 minutes, peak effects at 1–2 hours, and duration of approximately 6–8 hours. Etizolam itself has a half-life of approximately 6 hours and undergoes extensive hepatic metabolism; deschloroetizolam's metabolic pathways have not been definitively characterized.
Tolerance and Dependence
GABA-A receptor downregulation and subunit remodeling produce tolerance and physical dependence with regular use, identical in mechanism to classical benzodiazepines. The absence of clinical scheduling data does not reduce this risk.
Detection Methods
Standard Drug Panel Inclusion
Deschloroetizolam is NOT detected on standard drug panels. As a structural analogue of etizolam with the chlorine atom removed, it retains the thienodiazepine core that prevents cross-reactivity with conventional benzodiazepine immunoassay antibodies. Standard screening methods will produce negative results regardless of the amount consumed.
Urine Detection
Limited pharmacological data exists for deschloroetizolam. Based on its structural similarity to etizolam, urinary detection windows are estimated at 2 to 5 days after a single dose. The metabolic pathway likely involves CYP3A4-mediated hydroxylation and subsequent glucuronidation, producing metabolites structurally analogous to those of etizolam but lacking the chlorine substituent. Reliable detection requires LC-MS/MS methods that specifically include deschloroetizolam and its predicted metabolites in the analytical panel.
Blood and Serum Detection
Blood detection windows are estimated at 1 to 3 days. Pharmacokinetic data is sparse, and therapeutic concentration ranges have not been established in the clinical literature. Forensic case reports provide the primary source of blood concentration data.
Hair Follicle Detection
Hair analysis for deschloroetizolam is theoretically possible but has not been widely validated. Forensic laboratories with LC-MS/MS capability and appropriate reference standards could develop methods for this compound.
Confirmatory Methods
LC-MS/MS is the only viable confirmatory approach. The compound must be specifically included in the analytical panel with validated reference standards. GC-MS methods may also be applicable with appropriate derivatization protocols. Very few forensic laboratories routinely screen for deschloroetizolam, making detection dependent on clinical suspicion and specific analytical requests.
Reagent Testing
Reagent testing is unreliable for deschloroetizolam. No established colorimetric reactions have been documented for this specific compound. Given its thienodiazepine structure, faint responses to the Zimmermann and Mandelin reagents are possible but not diagnostic. Fentanyl test strips should be used on all products suspected to contain this compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 1,4-Butanediol | Dangerous | Combined CNS depression; risk of respiratory failure |
| 2M2B | Dangerous | Combined CNS depression; risk of respiratory failure |
| Acetylfentanyl | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Alcohol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Alprazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Atropa belladonna | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Baclofen | Dangerous | Combined CNS depression; risk of respiratory failure |
| Benzodiazepines | Dangerous | Combined CNS depression; risk of respiratory failure |
| Buprenorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Cake | Dangerous | Combined CNS depression; risk of respiratory failure |
| Carisoprodol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonidine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Codeine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Datura | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Desomorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Dextropropoxyphene | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Diclazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Dihydrocodeine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diphenhydramine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Eszopiclone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Ethylmorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Etizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| F-Phenibut | Dangerous | Combined CNS depression; risk of respiratory failure |
| Fentanyl | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Flualprazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gabapentin | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gaboxadol | Dangerous | Combined CNS depression; risk of respiratory failure |
| GBL | Dangerous | Combined CNS depression; risk of respiratory failure |
| GHB | Dangerous | Combined CNS depression; risk of respiratory failure |
| Grayanotoxin | Dangerous | Combined CNS depression; risk of respiratory failure |
| Harmala alkaloid | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Heroin | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Hydrocodone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Hydromorphone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Kratom | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Lorazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| MAOI | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Mephenaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Methadone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Methaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Metizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Midazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Mirtazapine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Morphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Myristicin | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Naloxone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Nicotine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Nifoxipam | Dangerous | Combined CNS depression; risk of respiratory failure |
| O-Desmethyltramadol | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Oxycodone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Oxymorphone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Peganum harmala | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Pentobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| Pethidine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Phenobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| SAMe | Dangerous | Combined CNS depression; risk of respiratory failure |
| 2-Aminoindane | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-FA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-FEA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-Fluorodeschloroketamine | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-FMA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 1,3-Butanediol | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1B-LSD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-AL-LAD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-LSD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-MiPLA | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
History
Emergence as a Research Chemical
Deschloroetizolam emerged in the research chemical market in the early-to-mid 2010s, following regulatory actions against etizolam in several countries. Like many designer thienodiazepines of this era, it appeared primarily through online vendors marketing to harm reduction communities and recreational users seeking GABAergic sedatives.
Regulatory Context
The compound's development and marketing followed the established pattern for novel psychoactive substances in the GABAergic depressant class: compounds appear in legal gray areas, experience periods of open sale, and are progressively scheduled as regulatory agencies respond to community reports and public health concerns. Deschloroetizolam has been subject to varying levels of control across jurisdictions, typically following actions against the parent compound etizolam.
Relationship to Etizolam
Etizolam itself has been licensed as a pharmaceutical in Japan (under the brand name Depas) since 1984 and in several other Asian countries. Its emergence in Western research chemical markets occurred as regulatory pressure built against pharmaceutical benzodiazepines, and deschloroetizolam represents one of several structural variations introduced as specific analogs were scheduled. The practice of producing close structural analogs to circumvent controlled substance laws has been a defining feature of the novel benzodiazepine and thienodiazepine markets of the 2010s and 2020s.
Harm Reduction
Weigh Doses Accurately
All thienodiazepines are highly potent and require accurate milligram-scale dosing. A milligram-accurate scale (0.001g precision) or volumetric dosing in solution is necessary — consumer-grade scales accurate only to 0.1g are inadequate.
Start Very Low
Without clinical dose-finding data, an initial dose should be conservative — a fraction of what user reports suggest as "standard" doses. Titrate cautiously with long intervals between adjustments.
Never Combine with Alcohol or Opioids
The combination of any GABAergic compound with opioids or alcohol significantly elevates respiratory depression risk. This rule is absolute.
Limit Frequency
To prevent physical dependence, use should be strictly limited in frequency. Ideally, thienodiazepines should not be used on consecutive days or more than once or twice per week maximum.
Taper If Dependent
If daily use has occurred for weeks, do not abruptly stop. Taper the dose gradually — ideally switching to an equivalent dose of a long-acting pharmaceutical benzodiazepine (e.g., diazepam) under medical supervision.
Obtain Naloxone
If opioids are present in the household or likely to be combined despite recommendations, having naloxone available and knowing how to use it could be life-saving.
Toxicity & Safety
Class Risk Profile
Deschloroetizolam shares the risk profile of all GABA-A positive allosteric modulators. Sole-agent overdose is rarely fatal in otherwise healthy individuals at doses encountered recreationally, but the combination with other CNS depressants — particularly alcohol and opioids — dramatically increases fatality risk.
Respiratory Depression
GABA-B and GABA-A enhancement at brainstem respiratory centers reduces hypercapnic drive and can produce respiratory failure at supratherapeutic doses, particularly in combination with opioids or alcohol.
Physical Dependence and Withdrawal
Regular use creates physical dependence within weeks. Withdrawal syndrome can include:
- Rebound anxiety and insomnia
- Tremor, diaphoresis, tachycardia
- Tonic-clonic seizures (potentially fatal without medical management)
- Delirium and psychosis in severe cases
Limited Clinical Data
The lack of formal pharmacological characterization means that dose-response relationships are poorly established. There is no clinical dose-finding to define safe dosing thresholds, increasing the risk of unintentional overdose.
Drug Interactions
- Alcohol — CNS and respiratory depression synergy
- Opioids — High-risk combination for respiratory arrest
- Other benzodiazepines/GABAergics — Additive CNS depression
- CYP3A4 inhibitors (e.g., grapefruit juice, azole antifungals) — May increase blood levels unpredictably
Addiction Potential
extremely physically and psychologically addictive
Overdose Information
Overdose
Thienodiazepine overdose may occur when a thienodiazepine is taken in extremely heavy quantities or concurrently with other depressants. This is particularly dangerous with other GABAergic depressants such as barbiturates and alcohol since they work in a similar fashion, but bind to distinct allosteric sites on the GABAA receptor, thus their effects potentiate one another. Thienodiazepine increase the frequency in which the chlorine ion pore opens on the GABAA receptor while barbiturates increase the duration in which they are open, meaning when both are consumed, the ion pore will open more frequently and stay open longer. Thienodiazepine overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not treated promptly and properly.
Symptoms of a thienodiazepine overdose may include severe thought deceleration, slurred speech, confusion, delusions, respiratory depression, coma or death. Thienodiazepine overdoses may be treated effectively in a hospital environment, with generally favorable outcomes. Thienodiazepine overdoses are sometimes treated with flumazenil, a GABAA antagonist, however care is primarily supportive in nature.
- Depressants** (1,4-Butanediol, 2-methyl-2-butanol, alcohol, barbiturates, GHB/GBL, methaqualone, opioids) - This combination can result in dangerous or even fatal levels of respiratory depression. These substances potentiate the muscle relaxation, sedation and amnesia caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Dissociatives** - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recove
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Tolerance
| Full | within a couple of days of continuous use |
| Half | Unknown |
| Zero | 7 - 14 days |
Cross-tolerances
Legal Status
Deschloroetizolam is a grey area compound within most parts of the world. This means that it is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
Canada: Thienodiazepines like deschloroetizolam are not scheduled in Canada. However, it is illegal to sell or give someone it for human consumption because it is not an approved medical drug.
Germany: Deschloroetizolam is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Russia: Deschloroetizolam is a Schedule III controlled substance since 2017.
Switzerland: Deschloroetizolam is a controlled substance specifically named under Verzeichnis E.
Turkey:** Deschloroetizolam is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: It is illegal to produce, supply, or import deschloroetizolam under the Psychoactive Substance Act, which came into effect on May 26, 2016.
Responsible use
Volumetric liquid dosing
Depressants
Deschloroetizolam (Wikipedia)
Deschloroetizolam (Isomer Design)
Deschloroetizolam (UKCR)
Experience Reports (1)
Tips (6)
Rebound anxiety after Deschloroetizolam wears off is often worse than the original anxiety. This drives a cycle of increasing use. Consider non-pharmacological anxiety management (therapy, exercise, meditation) as primary tools.
If you've been using RC benzos (including deschloroetizolam) daily, do not stop abruptly. Benzodiazepine and thienodiazepine withdrawal can cause seizures and be life-threatening. Taper gradually under medical supervision if possible.
Many pressed "Xanax" bars contain thienodiazepines like etizolam or deschloroetizolam instead of alprazolam, often at inconsistent doses. If you're taking pressed bars, you genuinely don't know what you're taking or how much. Fentanyl test strips and reagent kits are minimum precautions.
Deschloroetizolam is a thienodiazepine with less potency data available than established benzodiazepines. Dose carefully and start very low. Pressed pills sold as "Xanax" on the street frequently contain random RC benzos including deschloroetizolam — always test your substances.
Tolerance to the anxiolytic effects of Deschloroetizolam develops within weeks of daily use, but tolerance to the respiratory depression does NOT develop at the same rate. Escalating doses to chase anxiolysis increases overdose risk.
Start with the lowest effective dose of Deschloroetizolam. Benzodiazepines have steep dose-response curves and potency varies significantly between different compounds. What seems like a small increase can cause blackouts.
Community Discussions (1)
See Also
References (3)
- PubChem: Deschloroetizolam
PubChem compound page for Deschloroetizolam (CID: 827322)
pubchem - Deschloroetizolam - TripSit Factsheet
TripSit factsheet for Deschloroetizolam
tripsit - Deschloroetizolam - Wikipedia
Wikipedia article on Deschloroetizolam
wikipedia